BBIO Bridgebio announces FDA Acceptance of NDA for encaleret for adh1 Bridgebio Pharma - FDA sets pdufa target action date of may 8, 2027 fo
BBIO Bridgebio announces FDA Acceptance of NDA for encaleret for adh1 Bridgebio Pharma - FDA sets pdufa target action date of may 8, 2027 for encaleret NDA
Story updates
11:30:21 AM UTC
SquawkNews
BBIO - BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
11:31:42 AM UTC
SquawkNews
BBIO Bridgebio Pharma - FDA sets pdufa target action date of may 8, 2027 for encaleret NDA - FDA not planning advisory committee meeting for encaleret NDA - Phase 3 calibrate trial of encaleret in adh1 achieves all primary and key secondary endpoints - To initiate reclaim-hp phase 3 study of encaleret in chronic hypoparathyroidism
11:37:30 AM UTC
SquawkNews
BridgeBio announces FDA acceptance of encaleret NDA
BBIO Bridgebio Pharma - FDA sets pdufa target action date of may 8, 2027 for encaleret NDA - FDA not planning advisory committee meeting for encaleret NDA - Phase 3 calibrate trial of encaleret in adh1 achieves all primary and key secondary endpoints - To initiate reclaim-hp phase 3 study of encaleret in chronic hypoparathyroidism